Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Humatrope And Human Enhancement: Lilly Drug Featured In Bioethics Report

Executive Summary

FDA's approval of Humatrope for idiopathic short stature plays a prominent role in a report by the President's Council on Bioethics as an example of the blurry line between medical need and human enhancement

You may also be interested in...

BIO Creates Policy Chief Position, Plans Reports Justifying Biotech Prices

The Biotechnology Industry Organization is continuing to expand its reach into the health policy arena with the creation of a "chief of policy" position

Lilly Humatrope Postmarket Plans: Voluntary Study, No Patient Registry

An assessment of the long-term safety and efficacy of Lilly's Humatrope for idiopathic short stature will rely on a voluntary ongoing postmarket research program

Lilly Humatrope Short Stature Prescribing Criteria Recommended By Cmte.

Lilly should develop prescribing criteria to guide the use of Humatrope for non-growth hormone deficient short stature in pediatric patients, members of FDA's Endocrinologic & Metabolic Drugs Advisory Committee suggested during a June 10 meeting




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts